Form 4: Natera Executive Sells Shares Under Pre-Arranged Trading Plan

Natera, Inc.'s President of Clinical Diagnostics, Solomon Moshkevich, sold 3,000 shares of common stock on July 1, 2025, through a pre-arranged Rule 10b5-1 trading plan.

Summary

• Solomon Moshkevich, President of Clinical Diagnostics at Natera, Inc., sold a total of 3,000 shares of Natera common stock.
• The transactions occurred on July 1, 2025.
• The sales were executed under a Rule 10b5-1 trading plan established on November 26, 2024.
• The shares were sold at weighted average prices ranging from $163.8764 to $167.79 per share.
• Following these transactions, Moshkevich beneficially owns 130,205 shares of Natera common stock.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction disclosure (Form 4) under a pre-arranged trading plan, which typically does not indicate positive or negative sentiment about the company's prospects.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction, common across all industries for publicly traded companies. It does not provide specific industry-wide trends or competitive insights.

Stakeholder Impact

• Shareholders: Disclosure of insider trading activity, which can influence investor perception, though sales under 10b5-1 plans are often viewed as less impactful than open market sales.

Key Dates

Keywords

Natera, NTRA, Form 4, Insider Trading, Stock Sale, Solomon Moshkevich, Rule 10b5-1, Clinical Diagnostics, Biotechnology, Healthcare